Huahao Zhongtian rushes to the scientific and Technological Innovation Board: the annual loss is 280million, and it is proposed to raise 1.5 billion. Beida pharmaceutical is a shareholder

RedI network Lei Jianping 7 month 3 Reported Wednesday

Beijing Huahao Zhongtian biomedical Co., Ltd （ abbreviation ：“ Hua Hao Zhongtian ”） The prospectus was submitted a few days ago , Ready to be listed on the science and technology innovation board .

Huahao Zhongtian plans to raise funds 15 One hundred million yuan , among ,8 Billion yuan for innovative drug R & D projects ,3 Billion yuan is used for the industrialization of a class of anti-tumor new drug utidelon and the technical transformation and capacity expansion project of the base ,1 Billion yuan for marketing network construction projects ,3 Billion yuan to supplement working capital .

Years of losses 2.78 Billion

Huahao Zhongtian is an enterprise founded by a team of scientists studying in the United States , Relying on advanced combinatorial biosynthesis and other core technology platforms , Focus on developing new anticancer drugs with independent intellectual property rights . After nearly 20 The development of , The company has become a collection of new drug research and development 、 An integrated biomedical company integrating production and commercialization .

Countries independently researched and developed by the company 1 New drug of class A, uterol injection （ Trade name ： You ti Di ） It is a new generation of microtubule inhibitor produced by microbial fermentation process , On 2021 year 3 In June, it was approved by the State Drug Administration for listing .

Utidelon has a wide spectrum of anticancer , The results of previous studies show that for breast cancer 、 Lung cancer 、 Liver cancer 、 The antitumor activity of common tumors such as colon cancer and prostate cancer is better than paclitaxel , It also has a good effect on multi drug resistant tumors of paclitaxel and other chemotherapeutic drugs . Utidelon in the treatment of advanced breast cancer III The clinical results showed the efficacy and safety , Compared with the standard regimen, it improves the progression free survival and overall survival .

Hua Hao Zhongtian 2019 year 、2020 No revenue for the year , stay 2021 Annual revenue is 7106.4 Ten thousand yuan . Huahao Zhongtian is 2019 year 、2020 year 、2021 The annual net losses are 5592 ten thousand 、6525 Ten thousand yuan 、2.78 One hundred million yuan .

Beta pharmaceuticals 、 Longitude and latitude China 、 Dachen is a shareholder

Huahao Zhongtian has no controlling shareholder , The ownership structure is relatively decentralized .

IPO front , Tangli, the actual controller of the company （TangLi） And Qiu Rongguo （QiuRongGuo） Direct and indirect aggregate control company 29.47% shares , Tang Li （TangLi） And Qiu Rongguo （QiuRongGuo） Have control of the company , The two are husband and wife .

Tang Li （TangLi） ma'am , The current chairman and chief scientific officer of the company 、 Chief Marketing Officer ,1963 year 6 born , American nationality ; Qiu Rongguo （QiuRongGuo）, The current Vice Chairman of the company 、 The general manager , Directly manage the main affairs of the company , Qiu Rongguo （QiuRongGuo）1961 year 12 born , American nationality , Permanent residency in China .

among , North margin holdings of the United States 11.57%, Shanghai Xinsheng holds 9.94%, The shares held by SDIC venture capital fund are 8.41%, Shanghai Haidai holds 6.99%, Zhuhai Jingrong holds 5.83%, Zhuhai Huajin holds 5.49%,Matrix China The shareholding is 4.9%, Yifeng Ruihua holds 4.68%;

Beijing Chongde holds 4.44%, Zhuhai Huaxin holds 4%, Beijing Longpan entrepreneurship holds 3.99%, Shenzhen Dachen holds 3.66%, Zhang Haiyan holds shares of 3.18%, Beida pharmaceutical holds 3.18%, Zhongling Yanyuan holds 1.91%.

IPO after , Tang Li （TangLi） And Qiu Rongguo （QiuRongGuo） The shares of the controlling company will be reduced to about 25.78%.

North margin holdings of the United States 10.13%, Shanghai Xinsheng holds 8.7%, The shares held by SDIC venture capital fund are 7.36%, Shanghai Haidai holds 6.12%, Zhuhai Jingrong holds 5.1%, Zhuhai Huajin holds 4.81%,Matrix China（ Longitude and latitude China ） The shareholding is 4.29%, Yifeng Ruihua holds 4.09%;

Beijing Chongde holding 3.88%, Zhuhai Huaxin holds 3.5%, Beijing Longpan entrepreneurship holds 3.49%, Shenzhen Dachen Holdings 3.21%, Zhang Haiyan holds shares of 2.78%, Beida pharmaceutical holds 2.78%.

———————————————

Lei Di was founded by Lei Jianping, a senior media person , If reproduced, please indicate the source .